American Society of Hirudotherapy

Monomeric and Oligomeric Decorsins of the Asian Medicinal Leech

Tolksdorf C, Wolf R, Rauch BH, Jedlitschky G, Müller C (2025) · International Journal of Molecular Sciences · n=0

RCT evidence detailTrial reference
GRADE Very LowInsufficient evidenceLeech genomics and new leech molecules

Study Profile

Design
molecular biology, recombinant protein expression, and platelet aggregation functional study of decorsins encoded in the Hirudinaria manillensis (Asian buffalo leech) genome (Pharmacology and Toxicology, University Medicine Oldenburg and University Medicine Greifswald, Germany)
Sample size (n)
—
Intervention
Identification of one monomeric and four multimeric decorsin-encoding genes in the H. manillensis genome; recombinant expression, purification, and functional characterization of selected putative decorsins for platelet aggregation inhibition
Comparator
Cross-leech-species comparison with hirudin gene family and prior decorsin literature
Primary endpoint
Identification of decorsin-encoding genes; platelet-aggregation-inhibitory potency of recombinant decorsins; mathematical demonstration of alternative pre-mRNA splicing potential for combinatorial factor generation
Primary result
Five decorsin-encoding genes identified (one monomeric, four multimeric); all but one of the recombinant decorsins displayed platelet aggregation-inhibitory potency; mathematical analysis based on alternative pre-mRNA splicing demonstrates potential to generate enormous combinatorial diversity from a single multimeric ornatin gene; H. manillensis genome thus encodes both anticoagulant (hirudin) and antiplatelet (decorsin) factor families
Follow-up duration
not applicable (genomic and recombinant-protein mechanism study)
PMID
41303498

Key Findings

  • First systematic identification of decorsin-encoding genes (one monomeric, four multimeric) in the Asian buffalo leech (Hirudinaria manillensis) genome
  • Recombinant expression confirms platelet aggregation-inhibitory function for most decorsin variants
  • Mathematical analysis of alternative pre-mRNA splicing demonstrates large combinatorial diversity potential from a single multimeric ornatin gene
  • Extends the leech-pharmacology landscape from anticoagulants (hirudins, HLFs) to antiplatelet agents (decorsins, ornatins)
  • Asian medicinal leech species adds geographic and molecular diversity to the predominantly European hirudin-focused literature

Limitations

  • Mechanistic genomic and recombinant-protein study only - no clinical or in vivo data
  • Functional characterization limited to selected representative recombinant proteins
  • Platelet aggregation inhibition demonstrated in vitro; pharmacokinetics and bioavailability untested
  • Genome data interpretation depends on assembly quality and annotation completeness
  • Asian buffalo leech is not the principal commercial therapeutic species in the US or Europe

Clinical Implications

Tolksdorf 2025 expands the molecular pharmacology of medicinal leeches by characterizing decorsins, a family of antiplatelet factors distinct from the well-known hirudin anticoagulants. For ASH editorial purposes, the trial supports compound-registry pages that distinguish the multiple parallel mechanisms by which leech saliva contributes to hemostasis modulation. For US clinicians, the trial does not change practice but does provide important mechanistic context for understanding why whole-leech therapy produces a broader hemostatic effect than purified hirudin alone. The trial is cited as foundational mechanism literature alongside Müller 2016 and Wang 2018.

Related Trials

Hirudins and hirudin-like factors in Hirudinidae: implications for function and phylogenetic relationships

Müller C, Haase M, Lemke S, Hildebrandt JP (2016)

Diversity of hirudin and hirudin-like factor genes in the North-African medicinal leech, Hirudo troctina

Ahmed RB, Abilov A, Müller C (2024)

Molecular Insights into Leech-Derived Bioactive Compounds: Biochemical Mechanisms and Therapeutic Potential

Raghavi S, Deva Darshini B, Saravanan KM, Anbarasu K (2026)

Novel Sodium Channel Inhibitor From Leeches

Wang G, Long C, Liu W, Xu C, Zhang M, Li Q, Lu Q, Meng P, Li D, Rong M, Sun Z, Luo X, Lai R (2018)

← Back to RCT Library

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.